Brought to you by 
J&J plans to divest LifeScan unit to Platinum Equity for $2.1bn
26 Oct 2020
Executive Summary
Private investment firm Platinum Equity launched a binding offer to acquire Johnson & Johnson's blood glucose monitoring unit LifeScan Inc. for $2.1bn. J&J has until June 15, 2018 to accept the offer and if it does, the transaction is expected to close by year end.
Deal Industry
- Medical Devices
-
Medical Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Glucose Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J plans to divest LifeScan unit to Platinum Equity for $2.1bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice